Futura Medical (STU:GYX) EBITDA Margin %: 248.24% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Futura Medical EBITDA Margin %?

Futura Medical STU:GYX EBITDA Margin % is 248.24% as of Dec. 2025. The stock has 5 warning signs investors should review. Among 939 Biotechnology companies, Futura Medical ranks worse than 66.24% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Futura Medical's EBITDA for the six months ended in Dec. 2025 was €1.98 Mil. Futura Medical's Revenue for the six months ended in Dec. 2025 was €0.80 Mil. Therefore, Futura Medical's EBITDA margin for the quarter that ended in Dec. 2025 was 248.24%.

Futura Medical  (STU:GYX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Futura Medical EBITDA Margin % Related Terms

Futura Medical EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Futura Medical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Futura Medical EBITDA Margin % Chart

Futura Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -220.31 9.81 -290.77

Futura Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -353.30 12.56 7.03 -665.28 248.24

STU:GYX vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Futura Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Futura Medical EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Futura Medical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Futura Medical's EBITDA Margin % falls into.


Futura Medical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Futura Medical's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-5.641/1.94
=-290.77 %

Futura Medical's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=1.976/0.796
=248.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 248.24% mean?
Futura Medical (STU:GYX) has a EBITDA Margin % of 248.24% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Futura Medical and its competitors. According to the industry distribution chart, Futura Medical ranks #622 out of 939 companies in the Biotechnology industry, placing it in the top 66.2%.
Is Futura Medical's EBITDA Margin % too high?
Futura Medical's current EBITDA Margin % is 248.24%. Based on the distribution chart, Futura Medical ranks #622 out of 939 companies in the Biotechnology industry, which is below the industry midpoint.
How does Futura Medical's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Futura Medical ranks #622 out of 939 companies for EBITDA Margin %. This places Futura Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Futura Medical and its competitors. Futura Medical's current EBITDA Margin % is 248.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Futura Medical stock overvalued right now?
Futura Medical (STU:GYX) has a current EBITDA Margin % of 248.24%. The current EBITDA Margin % is 248.24%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Futura Medical (STU:GYX), the current EBITDA Margin % is 248.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Futura Medical Business Description

Address 40 Occam Road, Surrey Technology Centre, Guildford, Surrey, GBR, GU2 7YG
Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union.